Donna L Mcintosh

US Patent:

20090170928, Jul 2, 2009

Filed:

Oct 29, 2007

Appl. No.:

11/978540

Inventors:

Ferdinando F. Bruno - Andover MA, US
Jayant Kumar - Westford MA, US
Subhalakshmi Nagarajan - Dracut MA, US
Susan J. Braunhut - Wellesley MA, US
Ramaswamy Nagarajan - Dracut MA, US
Lynne A. Samuelson - Marlborough MA, US
Donna McIntosh - Chelmsford MA, US
Klaudia Foley - Littleton MA, US

International Classification:

A61K 31/352
C07D 407/02
C12P 17/16
A61P 35/00

US Classification:

514456, 549399, 435118

Abstract:

A method for synthesizing a biocompatible, water-soluble oligo/polyflavanoid, includes polymerizing an optionally substituted flavanoid with a polymerization agent in the presence of a biocompatible polymerization solubilizer, thereby producing the biocompatible, soluble oligo/polyflavanoid. Also included is a biocompatible, soluble, oligo/polyflavanoid or a pharmaceutically acceptable salt, solvate, or complex thereof. Also included are methods of treating a subject for cancer, cardiac damage, viral infection, and obesity.

US Patent:

20180195120, Jul 12, 2018

Filed:

Nov 27, 2017

Appl. No.:

15/823227

Inventors:

- Cambridge MA, US
Kristan Meetze - Lexington MA, US
Bin Feng - Newton MA, US
Steven Tyler - Boston MA, US
Steve Bottega - Cambridge MA, US
Richard Nicoletti - Southborough MA, US
Donna McIntosh - Chelmsford MA, US
Jeno Gyuris - Lincoln MA, US

International Classification:

C12Q 1/6881
G01N 33/574
A61K 39/395

Abstract:

A diagnostic method for predicting quantitatively whether a human tumor will be sensitive or resistant to treatment with an ERBB3 inhibitor, e.g, an anti-ERBB3 antibody, is disclosed. The method is based on measurement of NRG1 expression at the RNA level, or at the protein level, in a tissue sample from the tumor.

US Patent:

20140242597, Aug 28, 2014

Filed:

Oct 5, 2012

Appl. No.:

14/349916

Inventors:

- Cambridge MA, US
Kristan Meetze - Lexington MA, US
Bin Feng - Newton MA, US
Steven Tyler - Boston MA, US
Steve Bottega - Cambridge MA, US
Richard Nicoletti - Southborough MA, US
Donna McIntosh - Chelmsford MA, US
Jeno Gyuris - Lincoln MA, US

Assignee:

AVEO PHARMACEUTICALS, INC. - Cambridge MA

International Classification:

C12Q 1/68

US Classification:

435 612, 435 29

Abstract:

A diagnostic method for predicting quantitatively whether a human tumor will be sensitive or resistant to treatment with an ERBB3 inhibitor, e.g, an anti-ERBB3 antibody, is disclosed. The method is based on measurement of NRG1 expression at the RNA level, or at the protein level, in a tissue sample from the tumor.